Published in Haematologica on August 01, 2006
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol (2008) 1.04
Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol (2009) 0.92
Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease. Biochem J (2015) 0.78
CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia. Curr Pharm Biotechnol (2013) 0.77
Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia. J Blood Med (2011) 0.77
Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease. Ther Clin Risk Manag (2009) 0.76
Iron depletion: an ameliorating factor for sickle cell disease? ISRN Hematol (2011) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med (1995) 13.59
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
Pain in sickle cell disease. Rates and risk factors. N Engl J Med (1991) 9.75
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med (2005) 4.32
Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med (2002) 3.77
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) (2005) 3.33
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med (1993) 2.50
Predicting clinical severity in sickle cell anaemia. Br J Haematol (2005) 2.13
The paradox of hemoglobin SC disease. Blood Rev (2003) 1.75
Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood (1985) 1.54
The older sickle cell patient. Am J Hematol (2004) 1.50
Renal hemodynamic studies in adults with sickle cell anemia. Am J Med (1955) 1.49
Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med (1990) 1.47
Hypercoagulability in sickle cell disease: a curious paradox. Am J Med (2003) 1.47
Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med (1991) 1.46
A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant (2003) 1.28
Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int (1988) 1.16
Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med (1987) 1.15
Principles and problems of transfusion in sickle cell disease. Semin Hematol (2001) 1.12
Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci U S A (1993) 1.12
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol (2004) 1.07
A population study of renal function in sickle cell anemia. Int J Artif Organs (1990) 1.05
The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage (2004) 1.05
Effect of deoxygenation on blood rheology in sickle cell disease. Microvasc Res (1975) 1.03
Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood (1986) 0.98
Erythropoietin and renal function in sickle-cell disease. Br Med J (Clin Res Ed) (1982) 0.95
Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state. Hemoglobin (2000) 0.94
F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood (1993) 0.94
Acute renal failure in sickle cell anemia. Int J Artif Organs (1990) 0.90
Sickle cell disease and the kidney. Semin Nephrol (2003) 0.87
What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant (2005) 0.86
Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant (1992) 0.85
On the induction of fetal hemoglobin in the adult; stress erythropoiesis, cell cycle-specific drugs, and recombinant erythropoietin. Prog Clin Biol Res (1987) 0.84
Impaired creatinine secretion after an intravenous creatinine load is an early characteristic of the nephropathy of sickle cell anaemia. Nephrol Dial Transplant (2002) 0.84
Signaled expression of fetal hemoglobin during development. Transfusion (2005) 0.84
Automated oxyhemoglobin dissociation curve construction to assess sickle cell anemia therapy. J Natl Med Assoc (2000) 0.83
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. Acta Haematol (1995) 0.83
Erythropoietin therapy for sickle cell anemia in Jehovah's Witnesses. South Med J (1991) 0.82
Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. Hematol J (2000) 0.82
Rheology of sickle cells and its role in microcirculatory dynamics. Prog Clin Biol Res (1987) 0.82
A new hereditary persistence of fetal hemoglobin deletion has the breakpoint within the 3' beta-globin gene enhancer. Blood (1990) 0.82
Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med (1991) 0.81
The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin. Acta Haematol (1995) 0.79
Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol (1991) 0.79
Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience. Prog Clin Biol Res (1989) 0.78
Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. J Am Coll Surg (1998) 0.77
Deoxyhemoglobin S polymer formation in sickle cells. Blood (1986) 0.77
Erythropoietin and hemoglobin switching. Tex Rep Biol Med (1982) 0.77
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. Eur J Haematol (1996) 0.76
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med (2003) 8.95
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov (2008) 7.58
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA (2005) 6.49
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Sickle-cell disease. Lancet (2010) 5.64
Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med (2003) 4.98
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest (2005) 4.14
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med (2007) 3.29
Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest (2005) 3.08
Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res (2007) 2.91
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood (2005) 2.76
Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol (2006) 2.75
Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest (2005) 2.75
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA (2008) 2.55
Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA (2005) 2.47
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation (2007) 2.46
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
The reaction between nitrite and deoxyhemoglobin. Reassessment of reaction kinetics and stoichiometry. J Biol Chem (2005) 2.34
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
A Canadian screening program for hepatitis C: is now the time? CMAJ (2013) 2.33
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood (2007) 2.30
Catalytic generation of N2O3 by the concerted nitrite reductase and anhydrase activity of hemoglobin. Nat Chem Biol (2007) 2.30
Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol (2009) 2.29
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood (2012) 2.22
NO contest: nitrite versus S-nitroso-hemoglobin. Circ Res (2004) 2.21
Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica (2009) 2.20
Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2008) 2.17
Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev (2009) 2.15
Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation (2008) 2.14
The relationship between pulmonary emphysema and kidney function in smokers. Chest (2012) 2.13
Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med (2004) 2.09
Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood (2005) 2.08
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood (2004) 2.06
Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 2.06
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest (2003) 2.00
Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood (2010) 2.00
Racial difference in sarcoidosis mortality in the United States. Chest (2015) 1.93
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol (2012) 1.90
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA (2009) 1.88
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Methodologies for the sensitive and specific measurement of S-nitrosothiols, iron-nitrosyls, and nitrite in biological samples. Free Radic Res (2003) 1.81
Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol (2006) 1.79